Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus
Research is needed to help illustrate the size and nature of access gaps so that we can design better coverage policies. Ultimately, there is a need for policymakers to recognize that factors unrelated to whether an individual has a medical necessity for treatment can affect whether or not a person is likely to receive these medications, says study lead author Meghan Podolsky (SPH24), research fellow in the Department of Global Health and an SPH alum who completed the MS program in epidemiology last year
The Centers for Disease Control and Prevention (CDC) reports that more than 37 million Americans have diabetes, emphasizing the need for individualized therapies that improve glycemic control and long-term patient outcomes through precision-based drug interventions
These benefits include reductions in cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, as shown in landmark trials such as LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide)
Precision is essential, especially for patients who weigh more or have complex health conditions
This combined $197 bn market cap gain is 3.5x smaller than the gain of $697 bn realized from the launch of the GLP-1 products through 2024
